Compare AG & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | RGEN |
|---|---|---|
| Founded | 1979 | 1981 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.1B |
| IPO Year | 2004 | 1995 |
| Metric | AG | RGEN |
|---|---|---|
| Price | $26.84 | $123.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $21.92 | ★ $173.09 |
| AVG Volume (30 Days) | ★ 20.1M | 767.3K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $13.75 | $14.11 |
| Revenue Next Year | $26.43 | $14.71 |
| P/E Ratio | $143.01 | ★ $139.37 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $5.19 | $102.97 |
| 52 Week High | $32.00 | $175.77 |
| Indicator | AG | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 33.82 |
| Support Level | $20.21 | $121.25 |
| Resistance Level | $27.90 | $132.51 |
| Average True Range (ATR) | 1.81 | 6.58 |
| MACD | -0.49 | -0.05 |
| Stochastic Oscillator | 43.01 | 15.23 |
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.